Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38034882)

  • 1. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
    Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
    Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
    Long MD; Schreiber S; Hibi T; Gibble TH; Fisher DA; Park G; Moses RE; Higgins PDR; Lindsay JO; Lee SD; Escobar R; Jairath V
    Crohns Colitis 360; 2024 Jan; 6(1):otae001. PubMed ID: 38313767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
    Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
    J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38869019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
    Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
    J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
    N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
    D'Haens G; Higgins PDR; Peyrin-Biroulet L; Sands BE; Lee S; Moses RE; Redondo I; Escobar R; Gibble TH; Keohane A; Morris N; Zhang X; Arora V; Kobayashi T
    Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38271613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
    Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
    Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
    Chua L; Friedrich S; Zhang XC
    Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.
    Friedrich S; Chua L; Adams DH; Crandall W; Zhang XC
    Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38797892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
    Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
    Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Feb; ():10600280241229742. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
    Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.
    Johnson T; Steere B; Zhang P; Zang Y; Higgs R; Milch C; Reinisch W; Panés J; Huang K; D'Haens G; Krishnan V
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00630. PubMed ID: 37594044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.
    Dubinsky MC; Panaccione R; Lewis JD; Sands BE; Hibi T; Lee SD; Naegeli AN; Shan M; Green LA; Morris N; Arora V; Bleakman AP; Belin R; Travis S
    Crohns Colitis 360; 2022 Jul; 4(3):otac016. PubMed ID: 36777426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.